Skip to main content
. 2017 Nov 28;24(1):1818–1830. doi: 10.1080/10717544.2017.1407011

Figure 3.

Figure 3.

Tumor-homing characteristics of the ZPDGFRβ affibody. (A) Tumor uptake of the ZPDGFRβ affibody. CF750-labeled ZPDGFRβ affibody was intravenously injected into mice (n = 3) bearing subcutaneous LS174T tumor grafts (arrow indicated), followed by scanning with SPECTRAL Lago and Lago X Imaging Systems at different times (0–4 h) post-injection. (B) Bio-distribution of the ZPDGFRβ affibody in mice bearing LS174T tumor grafts. Mice (n = 3) injected with CF750-labeled ZPDGFRβ affibody were sacrificed at 4 h post-injection for optical imaging of organs/tissues. (C) Co-localization of the ZPDGFRβ affibody with CD31, PDGFRβ, or NG2 in tumor tissues. FAM-labeled ZPDGFRβ affibody was intravenously injected into mice bearing LS174T tumor grafts. Tumor grafts were removed and sectioned under freezing conditions, followed by staining with antibody against CD31, PDGFRβ, or NG2. The nuclei were visualized by DAPI staining. Original magnification 200×.